/
We are a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the 7 nicotinic acetylcholine ("ACh") receptor ("a7 receptor") for the acute, as needed treatment of social an…
The business is unprofitable at the operating level (-7.21% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (FY)
$16M
Net Income (TTM)
-$17M
▲ +97.6% YoY
Op. Margin
-7.21%
ROIC
-58.30%
▲ +65.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$17M
▲ +100.5% YoY
Net Debt
-$19M
Net Cash Position
Cash & Equiv.
$19M
Continue Research